As President Trump highlights his initiatives to reduce drug prices, Medicare's drug price negotiations, established amid the Biden administration, are ongoing. Companies like Novo Nordisk and Amgen have begun negotiations with the government over prices for 15 drugs, which includes the popular diabetes medication Ozempic. The government aims to finalize these prices by November 30, 2023, with reductions set to begin in January 2027. Health policy experts emphasize the necessity for the current administration to maintain the negotiation process as mandated by Congress, notwithstanding Trump's influence.
"It's a train that's sort of moving along the tracks in the background," says Ben Rome, a physician and health policy researcher at Harvard Medical School.
"Unless the Trump administration wants to sort of totally disregard the directives of Congress, then this process will continue," Rome says.
The first batch of 10 drugs was negotiated last year and announced in August with price cuts ranging from 79% for Type 2 diabetes drug Januvia to 38% for cancer drug Imbruvica.
Medicare is negotiating the prices of 15 drugs, including Novo Nordisk's Ozempic.
Collection
[
|
...
]